The CrickConnect team are delighted to be able to invite community members to join us for the institute's regular Crick Lecture.

Crick Lectures provide a broad insight into biomedical research from leading scientists. Not to be missed, the one-hour lectures are the event of the week for the Crick community to come together. The lectures aim to be accessible to scientists across different disciplines, while also offering something for the specialist.

This week, we're delighted to be joined by Mark Lemmon, Alfred Gilman Professor of Pharmacology at Yale University, and Director of the Yale Cancer Biology Institute, who will give this week's lecture ‘Understanding Receptor Tyrosine Kinases to Identify New Therapeutic Opportunities’

There will also be an opportunity to catch up with colleagues and friends over refreshments after the Lecture from 17:00. If you are able to join us in person at the Crick please let us know at connect@crick.ac.uk so we can arrange access.

Mark A Lemmon

The Lemmon group focuses on mechanistic, structural and biochemical aspects of signaling by growth factor receptor tyrosine kinases such as the EGF receptor, and on mechanism-guided targeted therapy in cancer. He has also contributed substantially to the field of signaling through phospholipids and phosphoinositides and to membrane protein folding. 

Educated in Oxford, U.K. (1st Class BA in biochemistry), Yale (PhD in molecular biophysics and biochemistry) and NYU (postdoc in pharmacology), he became an Assistant Professor of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine in 1996. He was promoted to Associate Professor in 2001, and to Full Professor in 2004. After two years as interim chair, Mark was appointed Chair of Biochemistry and Biophysics at Penn Medicine in 2010, and also became the George W. Raiziss Professor of Biochemistry and Biophysics.

After almost 20 years at Penn, he then returned to Yale in 2016 to initiate and co-direct the new Yale Cancer Biology Institute on West Campus as Professor of Pharmacology. He will also become Chair of Pharmacology at Yale in July 2023. 

Mark serves on advisory boards of several cancer research programs and companies, and on the Editorial Boards of Cell, Molecular Cell, Science Signaling, and several other journals. He is also Chair of the Editorial Board of the Biochemical Journal, and was Secretary of ASBMB from 2007 to 2013. Mark's honors include the Dean’s Award for Excellence in Graduate Student Training at Penn (2005), Penn’s Stanley Cohen Biomedical Research Award (2009), the Protein Society’s Dorothy Crowfoot Hodgkin Award (2012) and Yale Cancer Center’s Basic Science Research Award (2018). He was elected as a Fellow of the Royal Society (FRS) in 2016 and as an ASBMB Fellow in 2023.